Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s Critics
- Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s CriticsRE: Dendreon: Pro-Provenge Activists Heap Abuse on Cancer Drug’s CriticsThe final result has to show a 22% reduction in deaths. The interim showed a 20% reduction, closely matching previous trials. The final result of previous trials showed a 33% reduction...
- Discussion threads 2008-10-07
Additional Resources
- FDA panel backs Glaxo's new kidney cancer drug
- An expert panel gathered by the FDA has endorsed GlaxoSmithKline's new kidney cancer therapy, pazopanib. The group voted unanimously that the drug, which Glaxo plans to market as a treatment for advanced cases, had an acceptable benefit-to-risk ratio. The oral therapy is designed to stunt the growth of tumors by attacking...
- News items 2009-10-06
- BAYER LAUNCHED FIRST ANTI-CANCER DRUG IN CHINA
- AsiaInfo Services 12-13-2006 Bayer Launched First Anti-cancer Drug in China BEIJING, Dec 13, 2006 SinoCast via COMTEX -- Healthcare group of Bayer, German industrial giant, declared in Beijing that its anti-cancer drug Nexavar was approved by AsiaInfo Services ...
- Research articles 2006-12-13
- Imclone suffers on FDA refusal. (News).(US Food & Drug Administration rejects biologics license application for cancer drug Erbitux)(Brief Article)
- THE FOOD & DRUG Administration FDA dealt ImClone Systems Inc. a major blow when the agency recently rejected the company's biologics license application BLA filing for the cancer drug Erbitux. Bristol-Myers Squibb Company, which has agreed THE FOOD & DRUG Administration FDA dealt...
- Research articles 2002-01-07
- Arrowhead Research Subsidiary Insert Therapeutics Files IND Application for Anti-Cancer Drug Candidate IT-101; IT-101 Utilizes Cyclosert™, a Patented Nanotechnology-Based Drug Delivery Platform
- PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR) announced today that its majority-owned subsidiary Insert Therapeutics, Inc. has submitted an investigational new drug application IND to the U.S. Food and Drug Administration FDA for IT-101, its first anti-cancer drug candidate. IT-101 combines Insert's patented drug delivery platform, Cyclosert, and the anti-cancer...
- Research articles 2006-02-09
- Callisto Cites New Research Data on Cancer Drug Atiprimod in Presentations at American Society of Hematology Meeting; Company Announces Plan for Next Phase of Trial Following Release of Additional Clinical and Pre-Clinical Data
- NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug technologies in the fight against cancer and other serious healthcare threats, has released additional clinical research data on its cancer drug candidate Atiprimod, and further announced plans to extend the present Phase I/IIa clinical trial in multiple...
- Research articles 2005-12-14
- Astrazeneca PLC. (Active Pharmaceutical Ingredient Watch).(receives approval for Iressa cancer drug in Japan)(Brief Article)
- ASTRAZENECA PLC has received approval in Japan for cancer drug Iressa gefitinib 250 mg once daily tablets to treat inoperable or recurrent non-small cell lung cancer. Iressa ... ASTRAZENECA PLC has received approval in Japan for cancer drug Iressa gefitinib 250 mg once daily...
- Research articles 2002-07-15
- Yale and NFCR launch Research Center for Cancer Drug Design and Discovery.
- M2 PRESSWIRE-16 October 2006-YALE UNIVERSITY: Yale and NFCR launch Research Center for Cancer Drug Design and DiscoveryC1994-2006 M2 COMMUNICATIONS LTD RDATE:13102006 New Haven, Conn. - Yale University and the National Foundation for Cancer Research NFCR announced the establishment of an NFCR...
- Research articles 2006-10-16
- Penn Researchers Determine Structure of Binding Site of Colon-Cancer Drug and Its Protein Target; Findings Will Steer Future Treatment Design.
- Byline: University of Pennsylvania Health System PHILADELPHIA, April 18 AScribe Newswire -- Researchers at the University of Pennsylvania School of Medicine have determined the precise molecular details of how Erbitux, a recently approved colorectal cancer drug, binds to its target on cancer cells. Knowing...
- Research articles 2005-04-18
- Boulder, Colo.-Based Ribozyme Begins Study of Breast Cancer Drug.
- By Christine L. Romero, Daily Camera, Boulder, Colo. Knight Ridder/Tribune Business News Feb. 11--More patients fighting breast cancer will try Ribozyme Pharmaceuticals' promising anti-cancer drug with continued human clinical trials. Phase II trials of Angiozyme, made by the Boulder-based biotech ...
- Research articles 2001-02-11
- Genentech, OSI Pharmaceuticals target approval for Tarceva. (Life Sciences).(cancer drug)(Brief Article)
- GENENTECH INC. and OSI Pharmaceuticals Inc. saw their stocks climb last week after the Food and Drug Administration FDA awarded fast-track review status to cancer drug Tarceva (erlotinib, OSI-774). Tarceva is expected to compete with AstraZeneca GENENTECH INC. and OSI Pharmaceuticals Inc. saw...
- Research articles 2002-05-20
- Callisto Corporate Video Presentation Focuses on Company's Anti-Cancer Drug Candidates as Second Clinical Trial Starts; Video Presentation Spotlights Company's Drug Candidates to Treat Relapsed Leukemia and Multiple Myeloma Cancers
- NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, has released a corporate video presentation outlining the Company's current lead anti-cancer drug candidates, Atiprimod and L-Annamycin. Following the recent milestone launch of human clinical trials...
- Research articles 2005-12-09
- Roche launches cancer drug Tarveca in India.
- Apr. 12--MUMBAI, India -- Pharma major Roche Scientific on Tuesday announced the launch of its cancer drug, Tarveca erlotinib, in India. "This drug was launched in the US in October '04 and in the European Union in October '05", GL Telang Apr. 12--MUMBAI, India -- Pharma...
- Research articles 2006-04-12
- Callisto Issues Updated Investor Fact Sheet to Reflect Recent Clinical Progress of Cancer Drug Candidate Atiprimod; Drug's Clear Response Against Carcinoid Tumors and Newly Planned Clinical Development Direction Noted in Fact Sheet
- NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today announced the online availability of an updated Investor Fact Sheet that reflects recent important clinical results involving Atiprimod, one of the Company's cancer drug candidates. E[acute...
- Research articles 2006-03-02
- Simcere Shows Positive Data from Cancer Drug Trial
- ChinaBio Today submits: Simcere Pharma SCR reported that interim results from a Phase IV trial of its patented anti-cancer drug Endu showed the drug displayed both safety and efficacy. The data were in line with Endu’s Phase III trial. An anti-angiogenesis drug, Endu is a modified version of recombinant...
- External links 2008-09-03
- Novogen up 16c on cancer drug tests.(Brief Article)
- Mar 08, 2005 (The Australian - ABIX via COMTEX) The share price of Australian biotechnology company, Novogen, has risen as trials of its cancer drug proceed. Novogen's US subsidiary, Marshall Edwards, has progressed in its clinical trials of the drug, which is for the...
- Research articles 2005-03-08
- FDA Approves Stehlin Foundation for New Anti-Cancer Drug
- HOUSTON--HealthWire--Sept. 30, 1996--The Food and Drug Administration has granted the Stehlin Foundation for Cancer Research at St. Joseph Hospital exclusive rights to a promising anti-cancer drug for pancreatic cancer.
- Research articles 1996-09-30
- UK Nixes GSK Cancer Drug; Politics of Pricing Revealed
- UK Nixes GSK Cancer Drug; Politics of Pricing RevealedRE: UK Nixes GSK Cancer Drug; Politics of Pricing RevealedFT is wrong and so are you. There is a pre-test for Tykerb to determine if a woman is one of the 25 percent who would respond. Further, there are gene profiling tests...
- Discussion threads 2008-10-15
- Active pharmaceutical ingredient watch. (Markets: Life Sciences).(lung cancer drug fails to show survival benefit in Phase III trial, Roche Holding Ltd. receives approval for HIV drug)(Brief Article)
- ELI LILLY and Company and Isis Pharmaceuticals Inc. report that their antisense lung cancer drug Affinitak, a selective inhibitor of protein kinase Calpha expression, failed to show survival benefit versus chemotherapy in a Phase III trial evaluati ELI LILLY and Company and Isis Pharmaceuticals...
- Research articles 2003-03-24
- Melville, N.Y.-based firm may get expedited FDA approval for anti-cancer drug.
- By James Bernstein, Newsday, Melville, N.Y. Knight Ridder/Tribune Business News Jun. 30--OSI Pharmaceuticals Inc. yesterday said that its proposed anti-cancer drug has been accepted into a special federal program aimed at speeding up the normally lengthy approval process. The...
- Research articles 2004-06-30
- << Previous
- page 1 of 1
- Next >>
